{"resourceType":"Observation","id":"mii-exa-molgen-therapeutische-implikation-1","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/ext/modul-molgen/StructureDefinition/therapeutische-implikation","http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication"]},"status":"final","category":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/observation-category","code":"laboratory","display":"Laboratory"}]}],"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"therapeutic-implication","display":"Therapeutische Implikation"}]},"subject":{"reference":"Patient/mii-exa-molgen-patient"},"performer":[{"reference":"Practitioner/mii-exa-molgen-practitioner-lab"}],"derivedFrom":[{"reference":"Observation/mii-exa-molgen-variante-1"}],"component":[{"code":{"coding":[{"system":"http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs","code":"conclusion-string"}]},"valueString":"Nachweis einer aktivierenden Mutation BRAF V600E. Triple-Therapie mit einem EGFR-Antikörper sowie einem BRAF- und einem MEK- Inhibitor prüfen."},{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7","display":"Medication assessed [ID]"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.whocc.no/atc","code":"L01EC","display":"B-Raf serine-threonine kinase (BRAF) inhibitors"},{"system":"http://snomed.info/sct","code":"703645005","display":"Product containing B-Raf inhibitor (product)"}],"text":"BRAF Inhibitor"}},{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7","display":"Medication assessed [ID]"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.whocc.no/atc","code":"L01FE","display":"EGFR (Epidermal Growth Factor Receptor) inhibitors"}]}},{"code":{"coding":[{"system":"http://loinc.org","code":"51963-7","display":"Medication assessed [ID]"}]},"valueCodeableConcept":{"coding":[{"system":"http://www.whocc.no/atc","code":"L01EE","display":"Mitogen-activated protein kinase (MEK) inhibitors"}]}}]}